Perrigo Company PLC is working to catch-up on demand for its OTC cough/cold lines, likely missing $11m in revenues from the category in its latest quarter, at a time when sales are expected to jump for it and other consumer health product firms.
The firm’s doubts about delivering on projected demand for some OTCs combined with its report of a $49.4m net loss...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?